|
1
|
Dourthe ME, Simonin M, Rigaud C, Haouy S, Montravers F, Ducou Le Pointe H, Garnier N, Minard-Colin V, Jo Molina T, Boudjemaa S, Leblanc T, Landman-Parker J. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma]. Bull Cancer 2023; 110:968-977. [PMID: 37062647 DOI: 10.1016/j.bulcan.2023.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Revised: 03/06/2023] [Accepted: 03/08/2023] [Indexed: 04/18/2023]
Abstract
Nodular Lymphocyte predominant Hodgkin lymphoma (NLPHL) are rare lymphomas in pediatric patients comprising less than 10 % of all Hodgkin lymphoma (HL). They are for the most part diagnosed at stage I or II and indolent with lymphadenopathy often preceding the diagnosis by many months/years. Survival is excellent. Historically, patients were treated according to classical HL protocols. Due to high toxicity and excellent prognosis, management of NLPHL shifted to de-escalation protocol with good results. No treatment beyond surgical resection was proposed for localized unique nodal disease completely resected. The closed European protocol (EuroNet PHL LP1) evaluated the efficacy of low intensity chemotherapy protocol based on CVP courses (cyclophosphamide vinblastine prednisone) for stage IA/IIA not fully resected. Final results are not yet available. Advanced stage NLPHL are rare and there is no clinical trial and no consensus treatment in children. The SFCE lymphoma committee recently established recommendations for staging and treatment of limited and advanced NLPHL in children based on current practices and published results. The goal was to allow homogeneous practice on a national scale. If incomplete resection for patients with stage I/IIA combination of low intensity chemotherapy (CVP) and rituximab is recommended. For intermediary and advanced stage intensification with AVD (adriamycine vinblastine dacarbazine) or CHOP courses (cyclophosphamide doxorubicine vincristine prednisone) combined with rituximab are advocated. In children, there is no indication for first-line local treatment with radiotherapy.
Collapse
Affiliation(s)
- Marie Emilie Dourthe
- Université Paris Cité, hôpital universitaire Robert Debré, AP-HP, service d'immunologie et d'hématologie pédiatrique, Paris, France.
| | - Mathieu Simonin
- Sorbonne université Paris, hôpital Armand Trousseau, AP-HP, service d'hématologie pédiatrique, Paris, France
| | - Charlotte Rigaud
- Université Paris-Saclay, Gustave Roussy, département d'oncologie de l'enfant et de l'adolescent, Villejuif, France
| | - Stéphanie Haouy
- Hôpital universitaire de Montpellier, service d'hématologie et oncologie pédiatrique, Montpellier, France
| | | | - Hubert Ducou Le Pointe
- Sorbonne université, hôpital Armand Trousseau, AP-HP, service de radiologie, Paris, France
| | - Nathalie Garnier
- Hospices Civils de Lyon, institut d'hématologie et d'oncologie pédiatrique, Lyon, France
| | - Véronique Minard-Colin
- Université Paris-Saclay, Gustave Roussy, département d'oncologie de l'enfant et de l'adolescent, Villejuif, France
| | - Thierry Jo Molina
- Université Paris Cité, hôpitaux universitaires Necker Enfants Malades et Robert Debré, service d'anatomie pathologique, Paris, France
| | - Sabah Boudjemaa
- Sorbonne université, hôpital Armand Trousseau, AP-HP, service d'anatomie pathologique, Paris, France
| | - Thierry Leblanc
- Université Paris Cité, hôpital universitaire Robert Debré, AP-HP, service d'immunologie et d'hématologie pédiatrique, Paris, France
| | - Judith Landman-Parker
- Sorbonne université Paris, hôpital Armand Trousseau, AP-HP, service d'hématologie pédiatrique, Paris, France
| |
Collapse
|
|
2
|
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022; 57:1217-1239. [PMID: 35589997 PMCID: PMC9119216 DOI: 10.1038/s41409-022-01691-w] [Citation(s) in RCA: 177] [Impact Index Per Article: 59.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 04/15/2022] [Accepted: 04/20/2022] [Indexed: 12/17/2022]
|